<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix Closes Series D Financing - July 2011

    Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.

    Biodesix Selected to Present at Multi-State Investor and Partnering Conference

    Biodesix is one of 30 companies chosen to present at the regional conference held biennially by the Colorado BioScience Association (CBSA).

    Lung Cancer Study Evaluating Changes in VeriStrat Status over the Course of Treatment with Gefitinib Published in Journal of Thoracic Oncology

    Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.

    Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

    A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.

    Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award

    Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.

    Biodesix Receives New EU and US Patents for Blood-based Oncology Tests

    Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.

    Biodesix to Present at BioConference Live – Innovative Online Conference

    BioConference Live has selected Biodesix to present at the 5th annual Life Sciences conference, taking place online on October 26–27.

    VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer

    VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.

    VeriStrat® Test Predicts Outcomes in Advanced Breast Cancer Patients

    Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.

    Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon

    Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).